お知らせ • Mar 01
Jupiter Neurosciences, Inc. Receives Notice of Non-Compliance with Nasdaq Listing Standards
On February 26, 2026, Jupiter Neurosciences, Inc. (the “Company”) received two written notices (each, a “Notice” and together, the “Notices”) from the Listing Qualifications Department of Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that (i) the listing of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) was not in compliance with the minimum bid price requirement (the “Minimum Bid Price Requirement”) as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing of its Common Stock on The Nasdaq Capital Market, as the closing bid price of the Common Stock was less than $1.00 per share for the previous 30 consecutive business days, and (ii) for the 30 consecutive business days ended February 26, 2026, the Company’s market value of listed securities (“MVLS”) closed below the $35 million threshold required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). Nasdaq Listing Rule 5550(a)(2) requires companies to maintain a minimum bid price of $1.00 per share for its securities listed on The Nasdaq Capital Market, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s shares for the 30 consecutive business days prior to the Notice (January 13, 2026 through February 25, 2026), the Company no longer meets the Minimum Bid Price Requirement. However, under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until August 25, 2026, to regain compliance with the Minimum Bid Price Requirement. During the 180-day period, the Company may regain compliance under Listing Rule 5550(a)(2) if the bid price for the Company’s Common Stock is at least $1.00 for a minimum period of 10 consecutive business days. Nasdaq may, in its discretion, require the Company to maintain such closing bid price for a period in excess of 10 consecutive business days, generally no more than 20 consecutive business days, before determining that the Company has regained compliance. In the event that the Company does not regain compliance with the Minimum Bid Price Requirement by August 25, 2026, the Company may be eligible for additional time to regain compliance or may face delisting. To qualify for additional time, the Company will be required to meet the MVLS Requirement and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and must provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that its Common Stock will be subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel. Nasdaq Listing Rule 5550(b)(2) requires companies listed on The Nasdaq Capital Market to maintain a MVLS of $35 million. Based upon Nasdaq’s review of the Company’s MVLS for the last 30 consecutive business days, the Company no longer meets the MVLS Requirement. However, under Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days, or until August 25, 2026 (the “MVLS Compliance Period”), to regain compliance with the MVLS Requirement. During the 180-day period, the Company may regain compliance if the Company’s MVLS closes at or above $35 million for a minimum of 10 consecutive business days during the MVLS Compliance Period, upon which Nasdaq will provide written confirmation of compliance and the matter will be closed. In the event that the Company does not regain compliance with the MVLS Requirement within the MVLS Compliance Period, Nasdaq staff will provide written notice to the Company that its Common Stock is subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel. The receipt of the Notices has no immediate effect on the listing of the Company’s Common Stock, which will continue to trade uninterrupted on The Nasdaq Capital Market under the ticker “JUNS”. The Company intends to actively monitor its minimum bid price of its Common Stock and its MVLS, and, as appropriate, will consider available options to resolve the deficiencies and regain compliance with the Nasdaq Listing Rules, including, without limitation, effecting a reverse stock split. There can be no assurance that the Company will be successful in maintaining the listing of its Common Stock on The Nasdaq Capital Market.